Herantis Pharma Plc Announces Topline Results of Phase 1-2 CDNF Trial

Herantis Pharma Plc Announces Topline Results of Phase 1-2 CDNF Trial
HELSINKI, Feb. 25, 2020 /PRNewswire/ -- Topline analysis confirms positive safety and tolerability of CDNF in advanced-stage Parkinson's disease patients, with encouraging biological responses as measured by PET imaging in some patients. Results from the second part of trial, in which all ... read more
Source: PR NewswirePublished on 2020-02-25